Agenda

(members only)

(members only)

(board members and invited guests)

(board members and invited guests only)

Kick off Access! 2026 with a refined welcome reception that sets the tone for the days ahead, featuring a live harpist! Connect and converse with colleagues while enjoying refreshments— all while swaying to an elegant musical backdrop.

John Murphy III
President and CEO, AAM

2026 Champions of Access Award
American Consumer Institute

Tirzah Duren
President and CEO, American Consumer Institute

What’s happening on Capitol Hill and how we are working to position industry priorities with policymakers to make the most positive impact on patient access to affordable medicines.

Cristina Antelo, Esq.
Founding Principal and Chief Executive Officer, Ferox Strategies

Kate Hull
Senior Vice President, Fierce Government Relations

Moderator: Mark Ratner
Senior Vice President, Government Affairs, AAM

An insider’s view on policy, innovation, and the evolving regulatory environment.

Scott Gottlieb, M.D.
Former Commissioner, FDA
Former Senior Advisor, CMS

Moderator: John Murphy III
President and CEO, AAM

The role of pharmacy benefit managers (PBMs) has been a focus of drug pricing reforms in recent years. Opaque business practices and vertical integration across all channels of the prescription drug supply chain have raised serious questions about whether these entities are fulfilling their original purpose of reducing drug costs. Efforts to reform PBM business practices to bring more transparency and realignment of incentives have been frustratingly slow. Despite bipartisan consensus that legislation is needed to address PBM abuses, reforms have been mired in broader legislative gridlock. Now for the first time, Congress has enacted some substantive reforms – but stopped short of passing some of the more comprehensive measures that had been under consideration.

With more than 180 million Americans receiving health benefits through their job, employers are uniquely impacted by the market for pharmacy benefit services and are among those most strongly advocating for reform. This session will explore employers’ efforts to address PBM business practices, consider how the recently enacted reforms will impact the market, and discuss what comes next in the debate over these entities’ role in our healthcare system.

James Gelfand, JD
President and CEO, The ERISA Industry Committee (ERIC)

Moderator: Alex Keeton
Executive Director, Biosimilars Council
Senior Vice President, Policy, AAM

Communication about the value of pharmaceuticals is increasingly important, with the role of generics and biosimilars becoming clear at a time where the overall pharmaceutical ecosystem has been thrust into turmoil by dramatic policy proposals.

There is a need to put those policy efforts in a broader context to ensure that there is an understanding of how entire life science ecosystem – from the very earliest stages of discovery to the critical effort to make generic medicines widely available – fits together to drive maximal value for patients and society.

As such, there is a need for continuing education on the current landscape around external discussion of policy value, including different objectives, audiences to be considered, strategic approaches, and tactical considerations.

Brian Reid 
Founder and Principal, Reid Strategic
Senior Fellow, Tufts’ Center for the Evaluation of Value and Risk in Health

Moderator: Alex Keeton
Executive Director, Biosimilars Council
Senior Vice President, Policy, AAM

Analysts weigh in on the economic and investment climate impacting medicines.

(members only)

(members only)

Join us for a networking reception ahead of the evening’s dinner and entertainment. Enjoy refreshments while connecting with fellow attendees and exhibitors in a relaxed atmosphere before we transition into dinner.

An unforgettable evening of dining and music awaits—join us! We’ll gather for a seated dinner accompanied by an illuminated concert. Under the gentle glow of candlelight, embrace classical renditions of iconic hits from Queen vs. ABBA, a string quartet which promises to create a warm, serene atmosphere to close the day.

Unwind, celebrate, and end the night on a high note! Keep the evening going at our After Glow Party. Enjoy desserts, refreshing drinks, and a lively dance floor as USP’s house band, The Impurities, takes the stage with a high-energy setlist that includes rock-and-roll, punk, country, and pop anthems spanning decades—with original material mixed in too! With street cred garnered from performances at USP staff events, local bars, and large industry events, The Impurities have proven they’re not just a workplace band—they’re a force of fun!

Sponsored by:

John Murphy III
President and CEO, AAM

Outgoing AAM Chair’s Remark
Keren Haruvi
President of Sandoz North America, Sandoz

AAM Chair’s Address
Bob Hoffman
AAM Board Chair

Scott Cornwell
CEO, Dispensary of Hope

Experts unpack recent wins and milestones–and discuss what’s needed next to eliminate U.S. market uptake hurdles and fill the biosimilar void.

Balaji Prasad, M.D.
Chief Strategy Officer, Alvotech

Matt Erick
Chief Commercial Officer, Advanced Markets, Biocon Biologics

Moderator: Giuseppe Randazzo, M.S.
Senior Vice President, Sciences and Regulatory Affairs, AAM

Joseph M. Shields, Esq.
Chief Executive Officer, Transparency-Rx

Matt Wetzel, JD
Partner, Goodwin Procter LLP

Moderator: John Murphy III
President and CEO, AAM

Dive into the dynamics of global and U.S. generic and biosimilar markets. This session will examine market share trends, leading companies, fast-growing generic molecules and classes, ANDA approval patterns, retail pharmacy closures, drug shortages, and price deflation. Gain insights into biosimilar trends and future patent expirations shaping the industry’s future.

Scott Biggs 
Director, Supplier Services, IQVIA

AAM CEO John Murphy and Board Chair Bob Hoffman discuss critical policy and advocacy topics impacting generics and biosimilars with Bob Foster, Chief Counsel, Food, Research and Drugs, HHS.

Robert Foster, JD
Principal Deputy General Counsel and Chief Counsel for Food, Research, and Drugs
U.S. Department of Health and Human Services (HHS)

Moderator: Bob Hoffman
AAM Board Chair

Moderator: Maryll Toufanian, JD
Senior Vice President, Regulatory Strategy and Government Affairs, Amneal Pharmaceuticals Inc.

John Murphy III
President and CEO, AAM